Dr Link is a group leader at the Algarve Biomedical Center Research Institute (ABC-RI), and holds a position as an invited assistant professor at the Faculdade de Medicina e Ciências Biomédicas (FMBC) at the Universidade do Algarve (UAlg) in Faro. He has more than 20 years of experience in basic and translational biomedical research reflected in over 80 articles (38 as senior author, with 5744 citations) published in international peer-reviewed journals including PNAS, Nature, Nature Comm, Nature Rev. Drug Discovery, Oncogene, 2 books (Springer, Nature) and 7 book chapters. He holds three patents (one licensed to Sanofi Adventis GMBH), provided numerous invited key note and plenary presentations at international conferences and obtained competitive research funds from national and international (US and EU) sources. Dr. Link is a serial entrepreneur (Cofounder and CSO of biotech companies; Refoxy Pharmaceuticals, GMBH, Berlin/Boston - www.refoxy.com) and served as an advisor for pharmaceutical companies. He also serves as an editorial board member of prestigious, international peer reviewed journals including Cancers, Frontiers in Oncology and Frontiers in Cell and Developmental Biology. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published paper from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019). Dr Link obtained his PhD degree from the University of Hamburg, followed by a postdoc at CNB, Madrid before joining the pharma company EleGene AG (Germany) as a senior scientist. In 2001, he moved to Madrid joining the newly-founded CNIO where he was promoted to head the screening group in 2010. In 2012, he accepted a position as an assistant professor at the UAlg, Faro, Portugal where he was head of the Department of Oncobiology and director of the Masters program on Molecular mechanisms of cancer. In 2018, he also joined the Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM) in Madrid, Spain as a CSIC researcher and group leader. Dr Link has achieved consistent research excellence since 1995 and produced discoveries that have brought international reputation as a first-class researcher who has made substantial contributions to neuroscience and cancer research as well as to translational research and technology development. For over a decade, his research has been aimed at exploring and understanding the role of FOXO transcription factors in cancer and metabolism. A major breakthrough has been accomplished with the discovery of the FOXO repressor protein TRIB2 as a novel oncogene in melanoma. Recently the Link lab is extending the knowledge on the oncogenic role of TRIB2 to pancreatic cancer.

Identificação pessoal

Nome completo
Wolfgang Link

Nomes de citação

  • Link, Wolfgang

Identificadores de autor

Ciência ID
Google Scholar ID
Researcher Id
Scopus Author Id


  • https://cbmrualg.pt/ (Profissional)
  • https://www.refoxy.com/ (Profissional)
  • https://www.iib.uam.es/portal/en/home (Profissional)
  • https://scholar.google.com/citations?user=wPAcB10AAAAJ&hl=de (Académico)
  • http://orcid.org/0000-0002-3340-5165 (Académico)

Domínios de atuação

  • Ciências Médicas e da Saúde - Biotecnologia Médica
  • Ciências Naturais - Ciências Biológicas - Biologia Celular
  • Ciências Naturais - Ciências Biológicas - Biologia
  • Ciências Naturais - Ciências Biológicas - Biologia Molecular
  • Ciências Médicas e da Saúde - Medicina Clínica - Oncologia


Idioma Conversação Leitura Escrita Compreensão Peer-review
Alemão (Idioma materno)
Inglês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Espanhol; Castelhano Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Português Utilizador independente (B2) Utilizador independente (B2) Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1)
Grau Classificação
2000/03/15 - 2001/01/31
Centro Nacional de Biotechnologia (CNB) (Postgraduate Certificate)
Consejo Superior de Investigaciones Científicas, Espanha
1995/04/01 - 2000/03/14
Universität Hamburg (Doktor (PhD))
Universität Hamburg, Alemanha
"Molekulare und funktionelle Charakterisierung des transkriptionellen repressors DREAM" (TESE/DISSERTAÇÃO)
1994/04/01 - 1995/03/31
Diploma thesis (Master)
Universitätsklinikum Hamburg-Eppendorf Zentrum für Molekulare Neurobiologie Hamburg, Alemanha
"Die somatodentritische Expression eines bisher unbekannten, unmittelbar frühen gens wird durch synaptische Aktivität reguliert" (TESE/DISSERTAÇÃO)
1987/04/01 - 1994/03/31
Study of Biology (Licence)
Universität Hamburg Department Biologie, Alemanha
Percurso profissional


Categoria Profissional
Instituição de acolhimento
2011/12/01 - Atual Investigador principal (carreira) (Investigação) Universidade do Algarve - Campus de Gambelas, Portugal
Universidade do Algarve Centro de Investigação em Biomedicina, Portugal
2010/11/01 - 2011/11/30 Investigador principal (carreira) (Investigação) Centro Nacional de Investigaciones Oncológicas, Espanha
2001/09/01 - 2010/10/31 Investigador (Investigação) Centro Nacional de Investigaciones Oncológicas, Espanha
2000/10/01 - 2001/08/31 Investigador principal (carreira) (Investigação) Elegene GMBH, Alemanha

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento
2018/07/31 - Atual Professor Auxiliar Convidado (Docente Universitário) Universidade do Algarve - Campus de Gambelas, Portugal
2013 - 2018 Professor Auxiliar (Docente Universitário) Universidade do Algarve, Portugal

Cargos e Funções

Categoria Profissional
Instituição de acolhimento
2013 - 2018 Conselho científico/técnico-científico ou orgão correspondente Universidade do Algarve, Portugal


Categoria Profissional
Instituição de acolhimento
2020/12/01 - Atual Biotech Company Rexoxy Pharmaceuticals, GMBH, Alemanha


Designação Financiadores
2019 - 2021/09 Targeting TRIB2-mediated drug resistance in melanoma (RESIST)
Gobierno de España Ministerio de Ciencia Innovación y Universidades
2019 - 2020/08 Superar la resistencia a medicamentos en glioma
Gobierno de España Ministerio de Ciencia Innovación y Universidades
2019 - 2020/03/31 Using natural products from regional grapes/wine capable of regulating FOXO factors as potential anti-aging drugs
CBMR Synergy Grant 2019
Investigador responsável
Em curso
2017 - 2020/03/31 RED transfronteriza para el desarrollo de productos innovadores con microALGAs
Investigador responsável
Em curso
2019 - 2020/03 Using natural products from regional grapes/wine capable of regulating FOXO factors as potential anti-aging drugs
CBMR Synergy Grant 2019
2018 - 2019/11/30 Characterization of therapy-induced stabilization of the drug resistance protein TRIB2
Intermural CSIC grannt
Investigador responsável
Consejo Superior de Investigaciones Científicas, Espanha
2017 - 2018/01/31 Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma
LPCC-NRS/Terry Fox 2017-2018
Investigador responsável
Liga Portuguesa Contra o Cancro
2015 - 2016/05/31 Role of TRIB2 in the progression of Breast Cancer
Bolsa Laço 2015
Investigador responsável
Universidade do Algarve - Campus de Gambelas, Portugal
2014 - 2015/02/28 Impact of FOXO activators on aging
NIH U19 AG023122
Investigador responsável
National Institutes of Health
2014 - 2015/02 Impact of FOXO activators on aging
NIH U19 AG023122
National Institutes of Health
2013 - 2014/03 The role of tribbles homolog 2 (TRIB2) in drug resistance (e.g. to BAY 80-6946, and BAY 1082439, BAY 1001931 and BAY 86-9766) andits potential use as a biomarker to predict resistance to PI3K/Akt and MEK inhibitors
Grant4Target 2013
Bayer Corp
2006 - 2009/08/31 Identificación de compuestos líder y dianas terapéuticas: Utilización de la vía de PI3K/Akt para el descubrimiento de compuestos anticancerígenos
Investigador responsável
Gobierno de España
2002 - 2005/02/28 Desarrollo de ensayos celulares basados en la vía PI3’K/Akt para el descubrimiento de moléculas líder con potencial antitumoral
Investigador responsável
Gobierno de España


Designação Financiadores
2020 - Atual Developing small molecule FOXO activator compounds to treat age-related diseases and promote healthy aging
R&D Apollo
Em curso
2017 - 2020/08/31 TRIBBLES
Universidade do Algarve - Campus de Gambelas, Portugal
EU Framework Programme for Research and Innovation Marie Sklodowska-Curie Actions
Em curso


Artigo em revista
  1. Passirani, Catherine; Vessières, Anne; La Regina, Giuseppe; Link, Wolfgang; Silvestri, Romano. "Modulating undruggable targets to overcome cancer therapy resistance". Drug Resistance Updates 60 (2022): 100788. http://dx.doi.org/10.1016/j.drup.2021.100788.
  2. Faleiro, Inês; Roberto, Vânia Palma; Demirkol Canli, Secil; Fraunhoffer, Nicolas A.; Iovanna, Juan; Gure, Ali Osmay; Link, Wolfgang; Castelo-Branco, Pedro. "DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study". Cancers 13 24 (2021): 6354. http://dx.doi.org/10.3390/cancers13246354.
  3. Mónica T. Fernandes; Victor Yassuda; José Bragança; Wolfgang Link; Bibiana I. Ferreira; Ana Luísa De Sousa-Coelho. "Tribbles Gene Expression Profiles in Colorectal Cancer". Gastrointestinal Disorders 3 4 (2021): 218-236. https://doi.org/10.3390/gidisord3040021.
  4. Jimenez, Lucia; Silva, Andreia; Calissi, Giampaolo; Grenho, Inês; Monteiro, Rita; Mayoral-Varo, Victor; Blanco-Aparicio, Carmen; et al. "Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3". The Journals of Gerontology: Series A (2021): http://dx.doi.org/10.1093/gerona/glab265.
    Publicado • 10.1093/gerona/glab265
  5. Link, Wolfgang; Ilardi, Gennaro; Zannetti, Antonella. "Editorial: Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression". Frontiers in Oncology 11 (2021): http://dx.doi.org/10.3389/fonc.2021.730815.
    Publicado • 10.3389/fonc.2021.730815
  6. Bibiana I. Ferreira; Bruno Santos; Wolfgang Link; Ana Luísa De Sousa-Coelho. "Tribbles Pseudokinases in Colorectal Cancer". Cancers 13 11 (2021): 2825-2825. https://doi.org/10.3390/cancers13112825.
  7. Victor Mayoral-Varo; Lucía Jiménez; Wolfgang Link. "The Critical Role of TRIB2 in Cancer and Therapy Resistance". Cancers (2021): https://doi.org/10.3390/cancers13112701.
  8. Pérez-Beltrán, Christian Hazael; García-Guzmán, Juan José; Ferreira, Bibiana; Estévez-Hernández, Osvaldo; López-Iglesias, David; Cubillana-Aguilera, Laura; Link, Wolfgang; et al. "One-minute and green synthesis of magnetic iron oxide nanoparticles assisted by design of experiments and high energy ultrasound: Application to biosensing and immunoprecipitation". Materials Science and Engineering: C (2021): 112023. http://dx.doi.org/10.1016/j.msec.2021.112023.
    Acesso aberto • 10.1016/j.msec.2021.112023
  9. Giampaolo Calissi; Eric W.-F. Lam; Wolfgang Link. "Therapeutic strategies targeting FOXO transcription factors". Nature Reviews Drug Discovery (2021): https://doi.org/10.1038/s41573-020-0088-2.
  10. Machado S; Andreia Silva; Ana Luísa De Sousa-Coelho; Isabel Duarte; Inês Grenho; Bruno Santos; Victor Mayoral-Varo; et al. "Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance". Cancers (2020): https://www.mdpi.com/2072-6694/12/12/3689.
  11. Ferreira, Bibiana I.; Cautain, Bastien; Grenho, Inês; Link, Wolfgang. "Small Molecule Inhibitors of CRM1". Frontiers in Pharmacology 11 (2020): http://dx.doi.org/10.3389/fphar.2020.00625.
  12. Link, Wolfgang. "CRISPR/Cas9-mediated genome editing: From basic research to translational medicine". Journal of Cellular and Molecular Medicine (2020): http://dx.doi.org/10.1111/jcmm.14916.
  13. Cui, Bing; Eyers, Patrick A.; Dobens, Leonard L.; Tan, Nguan Soon; Mace, Peter D.; Link, Wolfgang; Kiss-Toth, Endre; et al. "Highlights of the 2nd international symposium on tribbles and diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer". (2019): http://hdl.handle.net/10400.1/12538.
  14. Henriques, V.; Martins, T.; Link, W.; Ferreira, B.I.. "The emerging therapeutic landscape of advanced melanoma". Current Pharmaceutical Design 24 5 (2018): 549-558. http://www.scopus.com/inward/record.url?eid=2-s2.0-85049050742&partnerID=MN8TOARS.
  15. Link, W.. "Knowledge-based drug discovery intensifies private appropriation of publicly financed research". The Lancet Oncology 19 8 (2018): 1017-1018. http://www.scopus.com/inward/record.url?eid=2-s2.0-85050801734&partnerID=MN8TOARS.
  16. Wolfgang Link; Pablo J. Fernandez-Marcos. "FOXO transcription factors at the interface of metabolism and cancer". International Journal of Cancer 141 12 (2017): 2379-2391. https://doi.org/10.1002/ijc.30840.
  17. Link W. "Immunology: Mind the immuno-connection gap.". (2017): http://europepmc.org/abstract/med/28437396.
  18. Hill R; Madureira PA; Ferreira B; Baptista I; Machado S; Colaço L; Dos Santos M; et al. "TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.". (2017): http://europepmc.org/abstract/med/28276427.
  19. Ferreira, B.I.; Lie, M.K.; Engelsen, A.S.T.; Machado, S.; Link, W.; Lorens, J.B.. "Adaptive mechanisms of resistance to anti-neoplastic agents". MedChemComm 8 1 (2017): 53-66. http://www.scopus.com/inward/record.url?eid=2-s2.0-85010716209&partnerID=MN8TOARS.
  20. Martins R; Lithgow GJ; Link W. "Long live FOXO: unraveling the role of FOXO proteins in aging and longevity.". (2016): http://europepmc.org/abstract/med/26643314.
  21. Cautain B; Castillo F; Musso L; Ferreira BI; de Pedro N; Rodriguez Quesada L; Machado S; et al. "Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling.". (2016): http://europepmc.org/abstract/med/27936162.
  22. Tarrado-Castellarnau M; Cortés R; Zanuy M; Tarragó-Celada J; Polat IH; Hill R; Fan TW; Link W; Cascante M. "Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.". (2015): http://europepmc.org/abstract/med/26375988.
  23. Hill R; Kalathur RK; Colaço L; Brandão R; Ugurel S; Futschik M; Link W; et al. "TRIB2 as a biomarker for diagnosis and progression of melanoma.". Biochemical Society Transactions 43 (2015): 1085-1088. http://europepmc.org/abstract/med/25586991.
  24. Wolfgang Link. "Molecular Inhibitors in Targeted Therapy". Molecular inhibitors in targeted therapy 1 1 (2015): https://doi.org/10.1515%2Fmotth-2015-0001.
  25. Cautain, B.; Hill, R.; De Pedro, N.; Link, W.. "Components and regulation of nuclear transport processes". FEBS Journal 282 3 (2015): 445-462. http://www.scopus.com/inward/record.url?eid=2-s2.0-84921797642&partnerID=MN8TOARS.
  26. Ferreira, B.I.; Hill, R.; Link, W.. "Caught in the crosshairs: Targeted drugs and personalized medicine". Cancer Journal (United States) 21 6 (2015): 441-447. http://www.scopus.com/inward/record.url?eid=2-s2.0-84948411505&partnerID=MN8TOARS.
  27. Ferreira BI; Hill R; Link W. "Special Review: Caught in the Crosshairs: Targeted Drugs and Personalized Medicine.". (2015): http://europepmc.org/abstract/med/26588674.
  28. Tarrado-Castellarnau, Miriam; Cortes, Roldan; Zanuy, Miriam; Tarrago-Celada, Josep; Polat, Ibrahim H.; Hill, Richard; Fan, Teresa W. M.; Link, Wolfgang; Cascante, Marta. "Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition". (2015): http://hdl.handle.net/10400.1/11207.
  29. Hill, Richard; Kalathur, Ravi Kiran Reddy; Callejas, Sergio; Colaço, Laura; Brandão, Ricardo; Serelde, Beatriz; Cebriá, Antonio; et al. "A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes". Breast Cancer Research 16 6 (2014): http://dx.doi.org/10.1186/s13058-014-0482-y.
  30. Hill, R.; Cautain, B.; De Pedro, N.; Link, W.. "Targeting nucleocytoplasmic transport in cancer therapy". Oncotarget 5 1 (2014): 11-28. http://www.scopus.com/inward/record.url?eid=2-s2.0-84893870810&partnerID=MN8TOARS.
  31. Mori, Mattia; Vignaroli, Giulia; Cau, Ylenia; Dinic, Jelena; Hill, Richard; Rossi, Matteo; Colecchia, David; et al. "Discovery of 14-3-3 Protein- Protein Interaction Inhibitors that Sensitize Multidrug- Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693". Chemmedchem 9 5 (2014): 973-983.
  32. Cortés, Roldán; Tarrado-Castellarnau, Míriam; Talancón, Daniel; López, Concepción; Link, Wolfgang; Ruiz, Daniel; Centelles, Josep Joan; Quirante, Josefina; Cascante, Marta. "A novel cyclometallated Pt(ii)–ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation". Metallomics 6 3 (2014): 622. http://dx.doi.org/10.1039/c3mt00194f.
  33. Cautain, Bastien; de Pedro, Nuria; Murillo Garzón, Virginia; Muñoz de Escalona, María; González Menéndez, Victor; Tormo, José R.; Martin, Jesús; et al. "High-Content Screening of Natural Products Reveals Novel Nuclear Export Inhibitors". Journal of Biomolecular Screening 19 1 (2013): 57-65. http://dx.doi.org/10.1177/1087057113501389.
  34. Link Wolfgang; Madureira Patricia; Hill Richard. "Identifying new targets for personalized medicine". eLS. John Wiley & Sons, Ltd: Chichester (2013):
    DOI: 10.1002/9780470015902.a0024865
  35. Granda, T.G.; Cebrián, D.; Martínez, S.; Anguita, P.V.; López, E.C.; Link, W.; Merino, T.; et al. "Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases". Investigational New Drugs 31 1 (2013): 66-76. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873832557&partnerID=MN8TOARS.
  36. Evensen, L.; Link, W.; Lorens, J.B.. "Image-based high-throughput screening for inhibitors of angiogenesis.". Methods in molecular biology (Clifton, N.J.) 931 (2013): 139-151. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873518972&partnerID=MN8TOARS.
  37. Zanella, F.; dos Santos, N.R.; Link, W.. "Moving to the Core: Spatiotemporal analysis of forkhead Box O (FOXO) and nuclear factor-¿B (NF-¿B) nuclear translocation". Traffic 14 3 (2013): 247-258. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873424232&partnerID=MN8TOARS.
  38. Wolfgang Link. "Nuclear accumulation of ß-catenin and forkhead box O3a in colon cancer: Dangerous liaison". World Journal of Biological Chemistry 3 9 (2012): 175-175. https://doi.org/10.4331%2Fwjbc.v3.i9.175.
  39. Kauselmann, G.; Dopazo, A.; Link, W.. "Identification of disease-relevant genes for molecularly-targeted drug discovery". Current Cancer Drug Targets 12 1 (2012): 1-13. http://www.scopus.com/inward/record.url?eid=2-s2.0-84855851646&partnerID=MN8TOARS.
  40. Martínez González, S.; Hernández, A.I.; Varela, C.; Rodríguez-Arístegui, S.; Lorenzo, M.; Rodríguez, A.; Rivero, V.; et al. "Identification of ETP-46321, a potent and orally bioavailable PI3K a, d inhibitor". Bioorganic and Medicinal Chemistry Letters 22 10 (2012): 3460-3466. http://www.scopus.com/inward/record.url?eid=2-s2.0-84860467003&partnerID=MN8TOARS.
  41. Martinez Gonzalez, Sonia; Isabel Hernandez, Ana; Varela, Carmen; Rodriguez-Aristegui, Sonsoles; Maria Alvarez, Rosa; Belen Garcia, Ana; Lorenzo, Milagros; et al. "Imidazo 1,2-a pyrazines as novel PI3K inhibitors". Bioorganic & Medicinal Chemistry Letters 22 5 (2012): 1874-1878.
  42. Martinez Gonzalez, Sonia; Isabel Hernandez, Ana; Varela, Carmen; Lorenzo, Milagros; Ramos-Lima, Francisco; Cendon, Elena; Cebrian, David; et al. "Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR". Bioorganic & Medicinal Chemistry Letters 22 16 (2012): 5208-5214.
  43. Link, W.. "Editorial". Current Drug Targets 12 9 (2011): 1232-1234. http://www.scopus.com/inward/record.url?eid=2-s2.0-79960000513&partnerID=MN8TOARS.
  44. Link, Wolfgang. "Context-dependent therapeutic potential of FOXO proteins in oral squamous cell carcinoma". Oral Oncology 47 4 (2011): 229-230.
  45. Hung, Mien-Chie; Link, Wolfgang. "Protein localization in disease and therapy". Journal of Cell Science 124 20 (2011): 3381-3392.
  46. Zanella, F.; Link, W.; Carnero, A.. "Understanding FOXO, new views on old transcription factors". Current Cancer Drug Targets 10 2 (2010): 135-146. http://www.scopus.com/inward/record.url?eid=2-s2.0-77950680198&partnerID=MN8TOARS.
  47. Evensen, Lasse; Micklem, David R.; Link, Wolfgang; Lorens, James B.. "A Novel Imaging-based High-throughput Screening Approach to Anti-angiogenic Drug Discovery". Cytometry Part a 77A 1 (2010): 41-51.
  48. Pastor, J.; Martinez, S.; Alvarez, R. M.; Varela, C.; Hernandez, A. I.; Rodriguez, S.; Oyarzabal, J.; et al. "Amino-alkyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K". Ejc Supplements 8 7 (2010): 62-62.
  49. Zanella, F.; Renner, O.; Garcia, B.; Callejas, S.; Dopazo, A.; Peregrina, S.; Carnero, A.; Link, W.. "Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells". Oncogene 29 20 (2010): 2973-2982.
  50. Evensen, Lasse; Link, Wolfgang; Lorens, James B.. "Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery". Current Pharmaceutical Design 16 35 (2010): 3958-3963.
  51. Rabal, Obdulia; Link, Wolfgang; Serelde, Beatriz G.; Bischoff, James R.; Oyarzabal, Julen. "An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries". Molecular Biosystems 6 4 (2010): 711-720.
  52. Zanella, Fabian; Lorens, James B.; Link, Wolfgang. "High content screening: seeing is believing". Trends in Biotechnology 28 5 (2010): 237-245.
  53. Link, W.. "Exploring the biological space of FOXO regulation: discovery of therapeutic targets and small molecule inhibitors for anticancer therapy". New Biotechnology 25 (2009): S3-S3.
  54. Zanella, Fabian; Rosado, Aranzazu; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators". Bmc Cell Biology 10 (2009):
  55. Link, Wolfgang; Oyarzabal, Julen; Serelde, Beatriz G.; Isabel Albarran, Maria; Rabal, Obdulia; Cebria, Antonio; Alfonso, Patricia; et al. "Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases". Journal of Biological Chemistry 284 41 (2009): 28392-28400.
  56. Carnero, Amancio; Blanco-Aparicio, Carmen; Renner, Oliver; Link, Wolfgang; Leal, Juan F. M.. "The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications". Current Cancer Drug Targets 8 3 (2008): 187-198.
  57. Rosado, Aranzazu; Zanella, Fabian; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "A Dual-Color Fluorescence-Based Platform to Identify Selective Inhibitors of Akt Signaling". Plos One 3 3 (2008):
  58. Zanella, Fabian; Rosado, Aranzazu; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "Chemical Genetic Analysis of FOXO Nuclear-Cytoplasmic Shuttling by Using Image-Based Cell Screening". Chembiochem 9 14 (2008): 2229-2237.
  59. Guijarro, Maria V.; Link, Wolfgang; Rosado, Aranzazu; Leal, Juan F. M.; Carnero, Amancio. "MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation". Carcinogenesis 28 12 (2007): 2443-2450.
  60. Liebel, Urban; Link, Wolfgang. "Meeting report: trends and challenges in high content analysis.". Biotechnology journal 2 8 (2007): 938-40.
  61. Zanella, Fabian; Rosado, Aranzazu; Blanco, Fernando; Henderson, Beric R.; Carnero, Amancio; Link, Wolfgang. "An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays". Assay and Drug Development Technologies 5 3 (2007): 333-341.
  62. Link, W; Rosado, A; Fominaya, J; Thomas, JE; Carnero, A. "Membrane localization of all class IPI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt". Journal of Cellular Biochemistry 95 5 (2005): 979-989.
  63. Link, WA; Ledo, F; Torres, B; Palczewska, M; Madsen, TM; Savignac, M; Albar, JP; Mellstrom, B; Naranjo, JR. "Day-night changes in downstream regulatory element antagonist modulator/potassium channel interacting protein activity contribute to circadian gene expression in pineal gland". Journal of Neuroscience 24 23 (2004): 5346-5355.
  64. Mellstrom, Britt; Torres, Begona; Link, Wolfgang A; Naranjo, Jose R. "The BDNF gene: exemplifying complexity in Ca2+ -dependent gene expression.". Critical reviews in neurobiology 16 1-2 (2004): 43-9.
  65. Moneo, V; Guijarro, MD; Link, W; Carnero, A. "Overexpression of cyclin D1 inhibits TNF-induced growth arrest". Journal of Cellular Biochemistry 89 3 (2003): 484-499.
  66. Carnero, A.; Blanco, C.; Blanco, F.; Castro, M.E.; Guijarro, M.V.; Fominaya, J.; Link, W.; et al. "Exploring cellular senescence as a tumor suppressor mechanism". Clinical and Translational Oncology 5 5 (2003): 249-265. http://www.scopus.com/inward/record.url?eid=2-s2.0-33646253025&partnerID=MN8TOARS.
  67. Sanz, C; Mellstrom, B; Link, WA; Naranjo, JR; Fernandez-Luna, JL. "Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic hrk gene in hematopoietic progenitor cells". Embo Journal 20 9 (2001): 2286-2292.
  68. Ledo, F; Carrion, AM; Link, WA; Mellstrom, B; Naranjo, JR. "DREAM-alpha CREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription". Molecular and Cellular Biology 20 24 (2000): 9120-9126.
  69. Link, WA; Kauselmann, G; Mellstrom, B; Kuhl, D; Naranjo, JR. "Induction of glycerol phosphate dehydrogenase gene expression during seizure and analgesia". Journal of Neurochemistry 75 4 (2000): 1419-1428.
  70. Ledo, F; Link, WA; Carrion, AM; Echeverria, V; Mellstrom, B; Naranjo, JR. "The DREAM-DRE interaction: key nucleotides and dominant negative mutants". Biochimica Et Biophysica Acta-Molecular Cell Research 1498 2-3 (2000): 162-168.
  71. Carrión, A.M.; Link, W.A.; Ledo, F.; Mellström, B.; Naranjo, J.R.. "DREAM is a Ca2+-regulated transcriptional repressor". Nature 398 6722 (1999): 80-84. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033521983&partnerID=MN8TOARS.
  72. Carrion, A.M.; Taylor, J.S.; Link, W.; Morcuende, S.; Mellsrtrom, B.; Naranjo, J.R.. "Early gene induction and spinal cord function". DOLOR 11 1 (1996): 22-24. http://www.scopus.com/inward/record.url?eid=2-s2.0-0029960761&partnerID=MN8TOARS.
  73. LINK, W; KONIETZKO, U; KAUSELMANN, G; KRUG, M; SCHWANKE, B; FREY, U; KUHL, D. "SOMATODENDRITIC EXPRESSION OF AN IMMEDIATE-EARLY GENE IS REGULATED BY SYNAPTIC ACTIVITY". Proceedings of the National Academy of Sciences of the United States of America 92 12 (1995): 5734-5738.
Entrada de dicionário
  1. Florindo, Claudia; Ferreira, Bibiana I; Serrão, Sónia M; Tavares, Álvaro A; Link, Wolfgang. "Subcellular Protein Localisation in Health and Disease". In eLS. John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9780470015902.a0026534.
  1. Link, W.. Introduction to FOXO biology. 2019.
  2. Barradas, M.; Link, W.; Megias, D.; Fernandez-Marcos, P.J.. High-throughput image-based screening to identify chemical compounds capable of activating FOXO. 2019.
  3. Machado, S.; Raposo, C.; Ferreira, B.I.; Link, W.. Image-based identification of chemical compounds capable of trapping FOXO in the cell nucleus. 2019.
  4. Link, W.. Preface. 2019.
  5. Wolfgang Link. FOXO Transcription Factors. Springer New York. 2019.
  6. Henriques, V.; Machado, S.; Link, W.; Ferreira, B.I.. Monitoring the transcriptional activity of FOXO transcription factors by analyzing their target genes. 2019.
  7. Link, Wolfgang. Principles of Cancer Treatment and Anticancer Drug Development. 2019.
  8. Cautain, B.; de Pedro, N.; Reyes, F.; Link, W.. Image-based identification of nuclear export inhibitors from natural products. 2015.
  9. Link, Wolfgang. International Manual of Oncology Practice. 2015.
  10. Evensen, L.; Link, W.; Lorens, J.B.. Image-based high-throughput screening for inhibitors of angiogenesis. 2012.
Recurso online
  1. Link, Wolfgang. Components and regulation of nuclear transport processes. 2015. http://www.yada-yada.co.uk/Blackwell/PAI/Audio/Wolfgang_Jan2015.mp3.
Tese / Dissertação
  1. Raposo, Catarina Martins. "Study of the TRIB2 protein network". Mestrado, 2019. http://hdl.handle.net/10400.1/13375.
  2. Henriques, Vanessa Mendes. "Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK". Mestrado, 2017. http://hdl.handle.net/10400.1/10705.
  3. Santos, Marta Machado Pereira dos. "Characterization of TRIB2-mediated resistance to anti-cancer drugs". Mestrado, 2016. http://hdl.handle.net/10400.1/8442.
  4. Silva, Neuton Pedro Gorjão da. "TRIB2 confers resistance to MAPK and TOR1 inhibitors". Mestrado, 2016. http://hdl.handle.net/10400.1/9833.
  5. Baptista, Inês do Carmo Viegas. "Characterization of TRIB2 following PI3K inhibition". Mestrado, 2015. http://hdl.handle.net/10400.1/7684.
  6. Colaço, Laura Guerreiro. "Investigating the role and function of Tribbles 2 (TRIB2) in drug resistance within cancer". Mestrado, 2014. http://hdl.handle.net/10400.1/8366.

Propriedade Intelectual

  1. Link, Wolfgang; Pastor J. F.. 2012. "New amino-imidazolothiadiazole compound useful for treating e.g. cancer, cardiovascular disease, viral infection, inflammation, neurological disorder, bone disorder, atherosclerosis, pulmonary fibrosisrestenosis, stroke, diabetes".
  2. Link, Wolfgang. 2003. "Caenorhabditis parkin gene and transgenic nematodes for use as Parkinson's disease models and for drug screening".
  3. Link, Wolfgang. 2000. "Calcium-dependent transcriptional regulator DREAM and its cDNA and methods for drug screening".


Empresa spin-off
  1. 2020. Refoxy Pharmaceuticals GMBH, Berlin/Boston. Drug Discovery. https://www.refoxy.com/.
  2. 2010. exCELLerate S.L.. Image-based Drug Discovery.
Outra produção
  1. Anti-cancer Drugs: Discovery, Development and Therapy. 2015. Wolfgang Link. https://doi.org/10.1007%2F978-3-319-21683-6_6.
  2. Finding novel targets for anticancer therapy. 2010. Link, W.. http://www.scopus.com/inward/record.url?eid=2-s2.0-77953451665&partnerID=MN8TOARS.

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2021/09/06 Emerging targets and small molecule drug candi-dates to overcome cancer therapy resistance, Invited talk, STRATAGEM, Annual conference 6th September 2021, Prague, Czech Republic STRATAGEM, Annual conference
STRATAGEM (Prague, República Checa)
2020/04/22 Tribbles pseudokinases in anti-cancer therapy resistance International Web Symposium, Pseudokinases and Tribbles - from Molecules to Therapy
Helmholtz Zentrum München, Germany (Madrid, Espanha)
2020/02/28 Targeting FOXO proteins to extend lifespan and fight cancer and anti-cancer drug resistance Invited talk, STRATAGEM, Annual conference 28th February 2020, Belgrade, Serbia STRATAGEM, Annual conference
COST (Belgrade, Sérvia)
2020/01/31 Spinning off academic discovery of FOXO - modulating compounds into small biotech companies TRANSAUTOPHAGY Translational Workshop
COST (Faro, Portugal)
2020/01/15 Harmine and Piperlongumine revert TRIB2-mediated drug resistance. Invited talk International Online Symposium on Synthesis and nanodelivery strategies for new therapeutic tools against Multidrug Resistant Tumours
COST STRATAGEM (Madrid, Espanha)
2019/09/20 Targeting the TRIB2 - FOXO axis of anti-cancer drug resistance; September 20, Invited Talk at General, Hospital of Vienna, Austria. Stratagem WG meeting
General Hospital of Vienna (Vienna, Áustria)
2019/06/07 Targeting FOXO proteins to fight cancer and extend lifespan; IIBM seminar, June 7, Madrid, Spain Seminar Cycle
IIBM (Madrid, Espanha)
2019/04/12 Tribbles proteins determine the level of activity of the oncokinase AKT Jornadas Liga Portuguese Contra o Cancro
Liga Portuguese Contra o Cancro, IPOLFG (Lisbon, Portugal)
2019/03/26 High content screening-based discovery of natural products from microalgae to treat cancer and slow aging, I Seminário Projeto ALGARED+, March 26, Faro, Portugal Seminário Projeto ALGARED+
CCMAR (Faro, Portugal)
2018/12/13 Targeting FOXO proteins to fight cancer and extend lifespan. “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” Conference, December 13, 2018, La Laguna, Tenerife, Spain Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” Conference
COST (tenerife, Espanha)
2018/10/16 TRIB2-mediated activation of AKT confers resistance to anti-cancer therapy, International workshop on The cell biology behind the ONCOGENIC PIP3 LIPIDS October 16, 2018, Baeza, Spain International workshop on “The cell biology behind the ONCOGENIC PIP3 LIPIDS
Universidad Internacional de Andalucía - Sede Antonio Machado de Baeza (Baeza, Espanha)
2018/05/29 Targeted strategies for the discovery of chemical compounds with therapeutic potential against cancer, Universidad de La Laguna, Instituto de Productos Naturales y Agrobiología del CSIC, May 29,2018, Tenerife, Spain Seminar
Universidad de La Laguna, Instituto de Productos Naturales y Agrobiología del CSIC (La laguna, Espanha)
2018/05/08 TRIB2 acts as a major driver of tumorigenesis and anti-cancer drug resistance 2th International Symposium on “TRIBBLES and Diseases"
TRIBBLES Network (Beijing, China)
2018/04/18 Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitors in the context of melanoma III Jornadas Liga Portuguese Contra o Cancro
Liga Portuguese Contra o Cancro (Lisbon, Portugal)
2018/03/03 Targeted drug discovery for Precision Oncology 5th MC/WG Meeting
COST Action CM1407 (Salini Resort, Malta)
2017/06/06 Characterization of TRIB2 mediated resistance to anti-melanoma drugs II Jornadas de Investigação em Oncologia em Portugal
IPOLFG (Lisbon, Portugal)
2017/05/19 Means to restore tumor suppressor genes in pancreatic cancer 2nd Porto Precision OONCOLOGY Meeting
IPATIMUP (Porto, Portugal)
2017/05/08 TRIB2, FOXO and p53: The evil axis of anti-cancer drug resistance 8th Meeting on Signal Transduction
SINAL (Lisbon, Portugal)
2017/03/03 FOXO Caught in the Crosshairs: Discovering Targets and Drugs for Innovative Anti-Cancer Therapies COST Annual Meeting
Jagiellonian University (Krakow, Polónia)
2016/10/06 TRIB2, FOXO and p53: The evil axis of anti-cancer drug resistance Invited seminar
University of Sheffield, Medical School, Sheffield (Sheffield, Reino Unido)
2016/06/18 FOXO Caught in the Crosshairs: Strategies of Innovative Drug Discovery Invited Seminar
CCMAR (faro, Portugal)
2016/06/08 TRIB2 as an oncogenic FOXO suppressor protein Tribbles Proteins at the Interface of Metabolism and Cancer
TRIBBLES network (Faro, Portugal)
2016/04/04 Discovering ways to tackle cancer drug resistance Invited seminar
IIBM-CSIC (Madrid, Espanha)
2016/02/12 TIBBLES breaking bad: TRIB2 confers resistance to anti-cancer drugs Invited seminar
IdiPAZ Madrid (Madrid, Espanha)
2015/04/23 TRIB2 acts as an oncogene in melanoma and confers drug resistance by deregulating the AKT signalling network Biochemical Society Conference, Tribbles at the crossroads of metabolism, cancer, immunity and development
Biochemical Society (Budapest, Hungria)
2014/10/14 Translocation in Cancer Therapy CIBICAN Conference on Molecular Pharmacology and Mechanisms of New Anticancer Drugs
CIBICAN (Tenerife, Espanha)
2013/07/05 Targeting the subcellular localization of tumor suppressors and oncogenic proteins as anti-cancer therapy Invited seminar
Fundación Medina, University of Granada (Granada, Espanha)
2013/06/21 FoxO Proteins as Potential Targets for Anti-Cancer Therapy FOXO3 and Related Transcription Factors in Development, Aging and Exceptional Longevity
Longevity Consortium, US (San Francisco, Estados Unidos)
2012/07/04 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of anti-cancer therapies Invited Seminar
Universita degli Studi di Milano (Milan, Itália)
2012/04/14 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of anti-cancer therapies SINAL2012, 6th National Meeting on Cell Signaling, University of Minho
SINAL (Braga, Portugal)
2012/03/16 Protein localization in disease and therapy 3rd Scientific Meeting of Institute for Biotechnology and Bioengineering Instituto Superior Técnico
Instituto Superior Técnico (Lisbon, Portugal)
2011/07/07 Protein localization in disease and therapy Invited seminar
nstitute for Biotechnology Bioengineering Dep. Ciências Biomédicas e Medicina, Universidade do Algarve (Faro, Portugal)
2011/06/14 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of therapeutic strategies Invited seminar
Institut de Recerca, Hospital Universitari Vall d'Hebron
2011/05/24 Pathway-oriented target and drug discovery for anticancer therapy Invited seminar
UKE Eppendorf, University Hamburg (Hamburg, Alemanha)
2011/05/17 Mislocalization and therapeutic restoration of normal protein localization in human diseases BD Biosciences Meeting
University Heidelberg (Heidelberg, Alemanha)
2010/06/24 High content imaging-based discovery of novel targets and small molecule inhibitors for anticancer therapy 2nd Annual Cellular Imaging Analysis,
Trinity College (Dublin, Irlanda)
2010/02/11 Image based pathway analysis of FOXO regulation leads to the discovery of therapeutic targets and small molecule inhibitors for anticancer therapy 22nd Lorne Cancer Conference
Lorne Cancer (Lorne, Austrália)
2009/10/21 A hierarchical network of image based screens and counter screens to explore strategies for restoring FOXO activity in human cancer 5th annual Global Imaging Summit
Global Imaging (Berlin, Alemanha)
2009/06/22 Exploring the Biological Space of FOXO Transcription Factors: Discovery of Kinase Inhibitors for Anticancer Therapy BIT's Annual World Cancer Congress
BTI (Beijing, China)
2008/09/10 Large-scale cell biology – Tackling the complexity of biological systems Invited Seminar
Centro Nacional de Investigaciones Cardiovasculares (CNIC) (Madrid, Espanha)
2008/08/02 Using High Content Cellular Imaging to crack the FOXO Code 4th annual Global Imaging Summit
GIS (cologne, Alemanha)
2008/07/09 Hunting with the Fox – Loss of Function screen identifies suppressors of FoxO function Informa´s MicroRNA & RNAi Industry Summit
Informa (London, Reino Unido)
2008/06/12 Screening for Content - Image-based Anticancer Drug Discovery BIT's Annual World Cancer Congress
BIT (Shanghai, China)
2008/03/11 Cellular pathway analysis using High-Content Imaging Informa´s 2nd annual High Content Analysis
Informa (berlin, Alemanha)
2008/03/06 High-Content Screening of complex RNAi and Compound libraries Invited seminar
University of Bergen (Bergen, Noruega)
2008/02/05 Screening for Content - Image-based Anticancer Drug Discovery Personalised Medicine Partnerships in Oncology & Cardiology
Next Level Pharma (Munich, Alemanha)
2008/01/09 Chemical genetic approach to study the regulation of nuclear-cytoplasmic shuttling of FoxO using High-Content Imaging CHI´s Fifth Annual High Content Analysis
CHI (San Francisco, Estados Unidos)
2007/06/29 Applying the Power of High Content Screening to Anti-Cancer Drug Discovery Invited Seminar
Centro de Investigación Príncipe Felipe (CIPF)
2007/06/27 High Content Screening-based Drug Discovery Informa´s High Content Analysis
Informa (Vienna, Áustria)
2007/06/08 An image-based approach to screen for inhibitors of the PI3K/Akt signaling pathway X Congreso de la Sociedad Ibérica de Citometría (SIC)
Sociedad Ibérica de Citometría (valencia, Espanha)
2006/09/29 Pathway specific anti-cancer drug discovery: Identification of therapeutic targets associated with PI3K/Akt signalling. Screening Europe
SEN (Prague, República Checa)
2006/09/26 Applying the Power of High Content Screening to Anti-Cancer Drug Discovery Invited Seminar
Institute for Research in Biomedicine (IRB) (Barcelona, Espanha)
2004/09/22 Development of cell - based high throughput assays targeting the PI3´K/Akt pathway for anti-cancer drug discovery III jornadas oncológicas CIC Apoptosis y Cáncer
CIC (Salamanca, Espanha)
2003/09/06 Day-Night changes in DREAM activity contribute to circadian gene expression in pineal gland X Congreso de la Sociedad Española de Neurosciencias
Sociedad Española de Neurosciencias (Lerida, Espanha)


Título / Tema
Papel desempenhado
Curso (Tipo)
Instituição / Organização
2017/04/01 - Atual Characterizing the role of FOXO regulators and FOXO isoforms in cancer
Universidade do Algarve, Portugal
2020/04/01 - 2021/03/31 Generation of drug resistant cell lines as a model to study melanoma, pancreatic cancer and glioblastoma.
Orientador de Inês Grenho
Universidade do Algarve, Portugal
2019/09/01 - 2021/01/29 Descoberta de moduladores de FOXO para tratamentos anticancerígenos e antienvelhecimento
Universidade do Algarve, Portugal
Universidade do Algarve, Portugal
2017/09/01 - 2018/06/30 Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK
Universidade do Algarve - Campus de Gambelas, Portugal
2016/09/01 - 2017/10/15 Study of the TRIB2 protein network
2014/09/01 - 2015/07/04 Characterization of TRIB2 following PI3K inhibition
Universidade do Algarve - Campus de Gambelas, Portugal
2014/09/01 - 2015/06/30 Characterization of TRIB2-mediated resistance to anti-cancer drugs
Universidade do Algarve - Campus de Gambelas, Portugal
2014/09/01 - 2015/06/30 TRIB2 confers resistance to MAPK and mTOR1 inhibitors
Universidade do Algarve - Campus de Gambelas, Portugal
2013/09/01 - 2014/06/30 Investigating the role and function of Tribbles 2 (TRIB2) in drug resistance within cancer
Universidade do Algarve - Campus de Gambelas, Portugal
2005/12/01 - 2009/05/08 Development of Technological Platforms for the identification of Novel Cellular Modulators of FOXO activity
Orientador de Fábian Zanella de Sá
Centro Nacional de Investigaciones Oncológicas, Espanha

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação)
Instituição / Organização
2020/01/30 - 2020/01/31 2nd Joint WG4-WG5 TRANSAUTOPHAGY, Faro/Portugal (2020/01/30 - 2020/01/31)
Congresso (Coorganizador)
2016/06/08 - 2016/06/09 International Meeting: ¿Tribbles Proteins at the Interface of Metabolism and Cancer (2016/06/08 - 2016/06/09)
Congresso (Presidente da Comissão Organizadora)
Universidade do Algarve - Campus de Gambelas, Portugal
2010/10/04 - 2010/10/05 BD Pathway Users Workshop (2010/10/04 - 2010/10/05)
Oficina (workshop) (Presidente da Comissão Organizadora)
2007/03/26 - 2007/03/27 High Content Analysis, Spain, 2007 (2007/03/26 - 2007/03/27)
Congresso (Presidente da Comissão Organizadora)
Centro Nacional de Investigaciones Oncológicas, Espanha

Arbitragem científica em conferência

Nome da conferência Local da conferência
2018/09/21 - 2018/09/22 SINAL, 9th Meeting on Signal Transduction SINAL

Comissão de avaliação

Descrição da atividade
Tipo de assessoria
Instituição / Organização Entidade financiadora
2019/10/01 - Atual TubInTrain Member of the international Evaluation Board of TubInTrain, European Joint Doctorate on chemistry and biology and focused on the microtubules breakdown (www.tubintrain.eu).

Consultoria / Parecer

Descrição da atividade Instituição / Organização
2019/10/01 - Atual Expert advisor for European FET Expert, Trendington; Prefet. Defining topics for European FET call
2001/03/01 - Atual Expert advisor for pharmaceutical industry Supervisor, Analysis of PI3K mutants for Eli Lilly, Indianapolis, EE UU Advisor, Consulting for Consorcio NanoFarma de vehiculización de fármacos (Drug delivery), project CENIT, Spain Advisor, Consulting for Bayer Pharma AG targeting Drug Resistance in Cancer Advisor, Apollo Ventures, funding anti-aging companies

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2006/10/01 - Atual Lecturer, PhD Course, University of Valencia (UV) Co-cordinator, Course on high content imaging, CNIO/Madrid Lecturer, Master Biotechnology, University of Barcelona (UB) Lecturer, ANGIOKEM, Rhodes, Greece Lecturer, Master Biotechnology, (UB) Lecturer, Master Biomedicine, UAlg Professor, Problem-based learning Medicine, UAlg Lecturer, Undergraduate Courses in Human genetics, UAlg Co-coordinator, Master Course Oncobiology, UAlg Lecturer, Signal Transduction, Cancer Therapy, Master Course, UAlg Lecturer, ESCCA Summer School (UV)

Outro júri / avaliação

Descrição da atividade Instituição / Organização
2012/03/11 - Atual EVALUATION FOR RESEARCH FUNDING ORGANISATIONS Austrian Science Fund (ASF, Austria) Dutch Cancer Society (Netherlands) European Research Council (European Union) FCT and Fundo iMM Laço (Portugal) Health Research Council New Zealand Italian Ministry of Health and Agenzia Italina del Farmaco (Italy) North West Cancer Research, Leuka and the Brain Tumour Charity (UK) Spanish Agency of Evaluation and Assessment (Spain) University of Cape Town (South Africa) University of Macau (China)
2012/03/01 - Atual PARTICIPATION IN INTERNATIONAL NETWORKS COST Action: CM1106, Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells COST Action: BM1204, An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease COST Action: CM1407, Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery Longevity Consortium, US (www.longevityconsortium.org)
2009/01/01 - Atual JOURNAL REVIEWER FOR (selected list) Biochemical J., Cancers, Carcinogenesis, ChemBioChem, Chemical Reviews, Current Medicinal Chemistry, Current Molecular Medicine, Drug Discovery Today, European Journal of Pharmacology, FEBS Letters, Frontiers in Immunology, Hepatology, J Cell Biochem, J Cell Science, J Cellular and Molecular Medicine, Medical Research Reviews, Nature Chemical Biology, Nature Comm., Neoplasia, Oncogene, Oncology Letters, Oral OncologyPloS ONE, PNAS, Redox Biology, Scientific Reports, Theranostics, Trends Cell Biology
2010/01/01 - 2020/12/31 JOURNAL REVIEWER FOR: Oxidative Medicine and Cellular Longevity, PloS ONE, PNAS, Redox Biology, Rejuvenation Research, Scientific Reports, SpringerPlus, Targeted Oncology, Trends Cell Biology, WJBC, World Journal of Medicine and Medical Science Research
2010/01/01 - 2020/03/31 JOURNAL REVIEWER FOR: Analytical Chemistry, Apoptosis, BBA - Molecular Basis of Disease, Biochemical J., Biotechniques, Biotechnology J, BMC Cell Biology, Cancer Drug Resistance, Carcinogenesis, ChemBioChem, Chemical Research in Toxicology, Chemical Reviews, Cellular Signalling, Current Medicinal Chemistry, Current Molecular Medicine, Cytometry A, Drug Discovery Today, EBioMedicine, European Journal of Pharmacology, Expert Opinion On Drug Discovery, F1000_Faculty Reviews, FEBS Letters, Gene, Gynecologic Oncology, Hepatology
2010/01/01 - 2020/03/31 JOURNAL REVIEWER FOR: International Journal of Cancer, Internat J Developmental Neurosci, International Journal of Oncology, J Biomol Screening, J Cell Biochem, J Cell Science, J Gastrointestinal and Liver Diseases, J Hematology & Oncology, J Inorg Biochem, Journal of Visualized Experiments, Life Sciences, Medical Research Reviews, Micromachines, Molecular Biology Reports, Molecular Imaging, Molecules, Nature Chemical Biology, Nature Comm., Neoplasia, Neuroscience Letters, Oncogene, Oncology Letters, Oncology Reports, Oncotarget, Oral Oncology


2000 PhD
Universität Hamburg, Alemanha